Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Heart muscle regeneration genes mapped

Researchers have uncovered insights into how stem cells develop and mature into heart muscle...

The cause of 2022's mpox outbreak revealed

Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...

New gene therapy treats liver disorder in growing children

Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...

Content from other channels on our network

$2.5m to double circuit breaker production in Adelaide

Long-term water security project proposed for Hunter region

Engineering sustainability from the ground up at Selfs Point STP

Complex solar installation for Adelaide wine venue

Australia's data centre plans can become a blueprint for the world

Nurse-led infection control training program

Does frailty hold the key to early dementia diagnosis?

Tiny gold particles power golden staph colour test

The cost of not cleaning: how to reduce infections and save money

WA's women's, newborn and children's model remains a "major missed opportunity", doctors say

APPEX 2027 is now open for registrations

Facing the manufacturing workforce challenges of the future

Paving the way for success with plant-based ingredients

Baiada Poultry opens its multimillion-dollar processing plant in Tamworth

NewCold's $200m expansion of cold storage facility in Vic